Biomarkers Predict Outcomes of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Songs of John Farnham: A Living Legend | Tony Cochrane (23.09.26) 7 min · 23 Sep 2026 · Whateley

Las 10 de Erazno, el Chokolatazo, Parodias, 1h 29m · 23 Sep 2026 · Erazno y La Chokolata El Podcast

Steve Hilton & Spencer Pratt: Fixing California, Cheaper Gas, Ballot Fraud & CA Republicans 55 min · 23 Sep 2026 · All-In with Chamath, Jason, Sacks & Friedberg

Optics of Alastair Clarkson's brunt sacking | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

The Eminently Sensible Phil Davis | Whateley (23.09.26) 13 min · 23 Sep 2026 · Whateley

The impact of Zak Butters' homecoming | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded24 Feb 2022

Publisherfeeds.buzzsprout.com

Handlerec:1648290

Show notes

Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program joins the Cancer Advances podcast to discuss research and findings that were presented at the 2021 American Society of Hematology Annual Meeting (ASH). Listen as Dr. Hill discusses how CAR T-Cell therapy may be a lifesaving option for patients with relapsed or refractory disease.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in